Simultaneous Estimation of Apremilast and Betamethasone Dipropionate in Microsponge-Based Topical Formulation using a Stability Indicating RP-HPLC Method: A Quality-by-Design Approach (original) (raw)
2021, Oxford University Press
A stability-indicating reverse phase high-performance liquid chromatography method was developed and validated for simultaneous quantification of apremilast (APL) and betamethasone dipropionate (BD) in bulk as well as drug loaded microsponges. Various mobile phase systems were screened to check the system suitability followed by force degradation analysis to determine APL and BD stability under varying stress conditions. A central composite design model was used to optimize the column temperature and flow rate using Design Expert ® (9.0.1). One factor at a time approach with five independent factors were used to validate the robustness of the method. Finally, APL and BD were precisely and accurately quantified from drug loaded microsponges using the validated method. A favorable separation of APL and BD was obtained on a Phenomenex ® Luna C18 column using a mixture of 50 mM phosphate buffer containing 0.1% triethylamine (pH 6.1) and acetonitrile (60:40%v/v) as mobile phase. Both the drugs were found to be stable when exposed to stressors such as heat-, light-, alkali-, acid-and peroxide-induced degradation. The calibration curves were found to be linear with appreciable limit of detection and limit of quantification. Recovery and percentage relative standard deviation of peak areas for APL and BD were found to be < 2.0% and 99-100% in bulk drug solution and <2.0% and 99-103% in microsponge formulation, respectively. Statistical analysis using analysis of variance indicated that the model was significant (P < 0.001). Hence, the developed method can be effectively used to quantify APL and BD, both in bulk as well as microsponge formulations.
Related papers
Devlopment and Validation of RP- HPLC Method for Estimation of Apremilast in Tablet Dosage Form
Journal of emerging technologies and innovative research, 2020
RP-HPLC for the determination of apremilast tablet dosage form the chromatographic s9999on was carried out UV 1700 detector, utilising C18 column (based on 99.999% ultra high purity silica ) 150 mm ×4.6 mm ,5μm particle size, utilising water methanol, triethylamine, at flow rate 1ml/min within injection vol. 20μl was selected for this study. The sepreation was carried out at a room temperature and the eluentant werw observed by photodiode array detector set a 264nm. The retention time of apremilast obtained was at 3.9 min. thus the propose method for APR was found to be feasible for estimation of APR in pharmaceutical dosage form. KeywordHPLC, Mobile phase,
International Journal of Pharmaceutical Sciences and Research, 2020
The aim of the present study is to develop a stability-indicating reverse-phase high-performance liquid chromatography method for the simultaneous estimation of Aspirin and Dipyridamole in combined extendedrelease dosage form 25/200mg, using a single unit of the capsule. Materials and Methods: Chromatographic separation was achieved with Agilent's highperformance liquid chromatography and X bridge C 8 column, with the mobile phase containing a mixture of ammonium dihydrogen phosphate buffer (pH 2.5): methanol (550:450, v/v) by isocratic elution technique. The flow rate was maintained at 1.2 ml/min, and the detection wavelength was 230nm. Results: Aspirin and Dipyridamole were eluted at 4.7min and 12.6min, respectively, using the developed method. The method was linear in the range of 12.5-50μg/ml for Aspirin and 100-400 μg/ml for Dipyridamole, with an r 2 value of 0.9997 and 0.9999, respectively. The sample recoveries observed were 97.63-100.96% and 97.38-98.01%, respectively, for aspirin and dipyridamole. The forced degradation studies were carried out, and the stressed samples were analyzed using the developed method. The purity angle of the peak was observed lesser than the threshold angle. Conclusion: The method could able to detect the potency of the product using one capsule. The recovery study results confirm the non-interference of formulation additives in the estimation. The purity angle from the forced degradation study confirms the non-interference from degradants in quantitating marketed formulation. Hence, the developed method is precise and accurate.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.